eScholarship
metadata only
CC BY-NC
Delayed-release rapamycin halts progression of left ventricular hypertrophy in subclinical feline hypertrophic cardiomyopathy: results of the RAPACAT trial
OBJECTIVE: Feline hypertrophic cardiomyopathy (HCM) remains a disease with little therapeutic advancement. Rapamycin modulates the mTOR pathway, preventing and reversing cardiac hypertrophy in rodent disease models. Its use in human renal allograft patients is associated with reduced cardiac wall th
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Mitochondrial Function in Transthyretin Amyloidosis#862776
- ATTR-Cardiomyopathy Stabilization Following Tafamidis Therapy#1183228
- A Systematic Review of Microsimulation Models in Cardiometabolic Disease: Model Calibration and Validation.#136024
- A Systematic Review of Microsimulation Models in Cardiometabolic Disease: Model Calibration and Validation#130639
- Aortic Stenosis and Stressed Heart Morphology#743877
Record · ID 1311330
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive